These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Landscape of Clinical Resistance Mechanisms to FGFR Inhibitors in FGFR2-Altered Cholangiocarcinoma. Wu Q; Ellis H; Siravegna G; Michel AG; Norden BL; Fece de la Cruz F; Balasooriya ER; Zhen Y; Silveira VS; Che J; Corcoran RB; Bardeesy N Clin Cancer Res; 2024 Jan; 30(1):198-208. PubMed ID: 37843855 [TBL] [Abstract][Full Text] [Related]
7. Futibatinib, an Irreversible FGFR1-4 Inhibitor, in Patients with Advanced Solid Tumors Harboring Meric-Bernstam F; Bahleda R; Hierro C; Sanson M; Bridgewater J; Arkenau HT; Tran B; Kelley RK; Park JO; Javle M; He Y; Benhadji KA; Goyal L Cancer Discov; 2022 Feb; 12(2):402-415. PubMed ID: 34551969 [TBL] [Abstract][Full Text] [Related]
8. Futibatinib, an investigational agent for the treatment of intrahepatic cholangiocarcinoma: evidence to date and future perspectives. Rizzo A; Ricci AD; Brandi G Expert Opin Investig Drugs; 2021 Apr; 30(4):317-324. PubMed ID: 33054456 [TBL] [Abstract][Full Text] [Related]
9. Understanding and Overcoming Resistance to Selective FGFR Inhibitors across FGFR2-Driven Malignancies. Facchinetti F; Loriot Y; Brayé F; Vasseur D; Bahleda R; Bigot L; Barbé R; Nobre C; Combarel D; Michiels S; Italiano A; Smolenschi C; Tselikas L; Scoazec JY; Ponce-Aix S; Besse B; André F; Olaussen KA; Hollebecque A; Friboulet L Clin Cancer Res; 2024 Nov; 30(21):4943-4956. PubMed ID: 39226398 [TBL] [Abstract][Full Text] [Related]
10. Robust Response to Futibatinib in a Patient With Metastatic FGFR-Addicted Cholangiocarcinoma Previously Treated Using Pemigatinib. Rengan AK; Denlinger CS J Natl Compr Canc Netw; 2022 Apr; 20(5):430-435. PubMed ID: 35378504 [TBL] [Abstract][Full Text] [Related]
11. Infigratinib for the Treatment of Metastatic or Locally Advanced Cholangiocarcinoma With Known FGFR2 Gene Fusions or Rearrangements. White K; Anwar AI; Jin K; Bollich V; Kelkar RA; Talbot NC; Klapper RJ; Ahmadzadeh S; Viswanath O; Varrassi G; Shekoohi S; Kaye AD Cureus; 2023 Oct; 15(10):e46792. PubMed ID: 37954763 [TBL] [Abstract][Full Text] [Related]
12. Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma. Krook MA; Lenyo A; Wilberding M; Barker H; Dantuono M; Bailey KM; Chen HZ; Reeser JW; Wing MR; Miya J; Samorodnitsky E; Smith AM; Dao T; Martin DM; Ciombor KK; Hays J; Freud AG; Roychowdhury S Mol Cancer Ther; 2020 Mar; 19(3):847-857. PubMed ID: 31911531 [TBL] [Abstract][Full Text] [Related]
13. Futibatinib Is a Novel Irreversible FGFR 1-4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors. Sootome H; Fujita H; Ito K; Ochiiwa H; Fujioka Y; Ito K; Miura A; Sagara T; Ito S; Ohsawa H; Otsuki S; Funabashi K; Yashiro M; Matsuo K; Yonekura K; Hirai H Cancer Res; 2020 Nov; 80(22):4986-4997. PubMed ID: 32973082 [TBL] [Abstract][Full Text] [Related]
14. Targeting FGFR in intrahepatic cholangiocarcinoma [iCCA]: leading the way for precision medicine in biliary tract cancer [BTC]? Aitcheson G; Mahipal A; John BV Expert Opin Investig Drugs; 2021 Apr; 30(4):463-477. PubMed ID: 33678096 [No Abstract] [Full Text] [Related]
15. A comprehensive overview of selective and novel fibroblast growth factor receptor inhibitors as a potential anticancer modality. Jain NK; Tailang M; Thangavel N; Makeen HA; Albratty M; Najmi A; Alhazmi HA; Zoghebi K; Alagusundaram M; Jain HK; Chandrasekaran B Acta Pharm; 2024 Mar; 74(1):1-36. PubMed ID: 38554385 [TBL] [Abstract][Full Text] [Related]
16. EGFR Inhibition Potentiates FGFR Inhibitor Therapy and Overcomes Resistance in FGFR2 Fusion-Positive Cholangiocarcinoma. Wu Q; Zhen Y; Shi L; Vu P; Greninger P; Adil R; Merritt J; Egan R; Wu MJ; Yin X; Ferrone CR; Deshpande V; Baiev I; Pinto CJ; McLoughlin DE; Walmsley CS; Stone JR; Gordan JD; Zhu AX; Juric D; Goyal L; Benes CH; Bardeesy N Cancer Discov; 2022 May; 12(5):1378-1395. PubMed ID: 35420673 [TBL] [Abstract][Full Text] [Related]
17. Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1-4 inhibitor in patients with advanced solid tumors. Bahleda R; Meric-Bernstam F; Goyal L; Tran B; He Y; Yamamiya I; Benhadji KA; Matos I; Arkenau HT Ann Oncol; 2020 Oct; 31(10):1405-1412. PubMed ID: 32622884 [TBL] [Abstract][Full Text] [Related]
18. Futibatinib: A Review in Locally Advanced and Metastatic Cholangiocarcinoma. Hoy SM Target Oncol; 2024 May; 19(3):473-480. PubMed ID: 38724820 [TBL] [Abstract][Full Text] [Related]
19. Discovery of Futibatinib: The First Covalent FGFR Kinase Inhibitor in Clinical Use. Ito S; Otsuki S; Ohsawa H; Hirano A; Kazuno H; Yamashita S; Egami K; Shibata Y; Yamamiya I; Yamashita F; Kodama Y; Funabashi K; Kazuno H; Komori T; Suzuki S; Sootome H; Hirai H; Sagara T ACS Med Chem Lett; 2023 Apr; 14(4):396-404. PubMed ID: 37077386 [TBL] [Abstract][Full Text] [Related]
20. Pemigatinib in cholangiocarcinoma with a FGFR2 rearrangement or fusion. Storandt MH; Jin Z; Mahipal A Expert Rev Anticancer Ther; 2022 Dec; 22(12):1265-1274. PubMed ID: 36408971 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]